Skip to main content
Premium Trial:

Request an Annual Quote

Great Basin Q4 Revenues Rise 37 Percent

NEW YORK (GenomeWeb) – Great Basin today reported a 37 percent year-over-year increase in its fourth quarter revenues due to growth in its customer base and initial adoption of its Group B Strep assay.

For the three months ended Dec. 31, 2015, the Salt Lake City-based firm posted $611,870 in revenues, up from $445,283 in the previous year.

The firm reported a net loss of $18.9 million, or $5.15 per share, compared to a net income of $1.5 million, or $8.39 per share, in Q4 2014. It used about 3.7 million common shares to compute EPS in 2015 compared to 179,212 shares in the year-ago period. Great Basin went public in October 2014.

The firm's Q4 R&D spending increased approximately 69 percent to $2.2 million due to costs associated with clinical trials and regulatory activities related to the firm's Staph ID/R Blood Culture and Shiga Toxin Direct assays as well as pipeline growth.

The firm's SG&A costs nearly doubled year over year to $3.9 million from $2.0 million attributed in part to additional sales force hires and increased business activities.

For full-year 2015, Great Basin recorded $2.1 million in revenues compared to $1.6 million in 2014. Its net loss for 2015 was $57.9 million, or $51.17 per share, compared to a net loss of $21.7 million, or $1,039.41 per share, in 2014.

The company calculated its net loss for 2015 using approximately 1.1 million shares, compared to 20,904 shares in 2014.

Full-year R&D costs rose 84 percent year over year to $8.5 million from $4.6 million, while its SG&A costs more than doubled to $11.2 million from $5.2 million.

Great Basin finished 2015 with $4.8 million in cash and $13.8 million in restricted cash. On a conference call following the earnings release, the firm also noted it is planning a special meeting of its board to decide whether to reverse split its stock in order to potentially attract larger institutional investors and stave off Nasdaq delisting. 

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.